STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [8-K] Keros Therapeutics, Inc. Reports Material Event

[8-K] Keros Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock KROS logo
Keros Therapeutics, Inc.

NASDAQ:KROS

KROS Rankings

#4411 Ranked by Market Cap
N/A Ranked by Dividends

KROS Latest News

Jul 17, 2025
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Jun 9, 2025
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Jun 9, 2025
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Jun 6, 2025
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
May 29, 2025
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

KROS Latest SEC Filings

Jul 15, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Jun 24, 2025
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity

KROS Stock Data

581.61M
38.64M
2.3%
104.03%
10.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
LEXINGTON